Clinical Study

Nomogram Predicting Renal Insufficiency after Nephroureterectomy for Upper Tract Urothelial Carcinoma in the Chinese Population: Exclusion of Ineligible Candidates for Adjuvant Chemotherapy

Dong Fang,1 Qifu Zhang,2 Xuesong Li,1 Cheng Qian,1 Gengyan Xiong,1 Lei Zhang,1 Xiaopeng Chen,1,3 Xiaoyu Zhang,1 Wei Yu,1 Zhisong He,1 and Liqun Zhou1

1 Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China
2 Department of Urology, Jilin Tumor Hospital, No. 1018 Huguang Road, Chaoyang District, Changchun, Jilin 130021, China
3 Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Baqiao District, Xi’an, Shaanxi 710038, China

Correspondence should be addressed to Xuesong Li; pineneedle@sina.com and Liqun Zhou; zhoulqmail@sina.com

Received 24 April 2014; Revised 26 June 2014; Accepted 16 July 2014; Published 10 August 2014

Academic Editor: Shen-Yang Lee

Copyright © 2014 Dong Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To report the decline of renal function after radical nephroureterectomy (RNU) in upper tract urothelial carcinoma (UTUC) patients and to develop a nomogram to predict ineligibility for cisplatin-based adjuvant chemotherapy (AC). Methods. We retrospectively analyzed 606 consecutive Chinese UTUC patients treated by RNU from 2000 to 2010. We chose an eGFR of 60 and 45 ml/min/1.73 m² as cut-offs for full-dose and reduced-dose AC eligibility. Results. Median eGFR for all patients before and after surgery was 64 and 49 ml/min/1.73 m² (P < 0.001). The proportion of patients ineligible to receive full-dose and reduced-dose AC changed from 42% to 74% and from 20% to 38.1%. Older age (OR = 1.007), preoperative eGFR (OR = 0.993), absence of hydronephrosis (OR = 0.801), smaller tumor size (OR = 0.962), and tumor without multifocality (OR = 0.876) were predictive for ineligibility for full-dose AC. Preoperative eGFR (OR = 0.991), absence of hydronephrosis (OR = 0.881), tumor located in renal pelvis (OR = 1.164), and smaller tumor size (OR = 0.969) could predict ineligibility for reduced-dose AC. The c-index of the two models was 0.757 and 0.836. Postoperative renal function was not associated with worse survival. Conclusions. Older age, lower preoperative eGFR, smaller tumor size, tumor located in renal pelvis, and absence of hydronephrosis or multifocality were predictors of postoperative renal insufficiency.

1. Introduction

Although radical nephroureterectomy (RNU) with excision of the bladder cuff is the gold-standard treatment for upper tract urothelial carcinomas (UTUC) [1], the oncologic outcomes for patients with high-grade or non-organ-confined disease remain poor, with 5-year cancer-specific survival rates less than 60% [2–4]. Multimodal approaches have been suggested and perioperative chemotherapy has been considered as an option to improve disease control [5–7].

The use of cisplatin-based chemotherapy has gained greater acceptance as evidenced by its use in neoadjuvant and adjuvant therapy, especially in patients with pT3-4 or pTxN+ [5–8]. But cisplatin-based therapy was associated with a higher risk of severe nephrotoxicity, and creatine clearance was important in determining whether patients should be treated with cisplatin [9]. However, the present limited ability to predict tumor stage and grade accurately before surgery makes it difficult to select proper candidates for neoadjuvant
therapy, while the loss of renal unit would limit the use of cisplatin-based chemotherapy in adjuvant therapy [10, 11].

Several reports have evaluated changes in renal function following RNU and demonstrated that the decline in renal function may render a substantial number of patients ineligible to receive adjuvant chemotherapy (AC) [10–15]. The ability to predict which patients would develop renal insufficiency following RNU would be extremely useful. Previous studies provided scarce information on risk stratification for worse chronic kidney disease (CKD) after RNU [13–15], and there are few published reports from research centers in China.

Therefore, in this large single-center cohort of patients, we sought to reveal the prevalence of CKD before and after RNU and to develop a nomogram to predict ineligibility for AC, which would help to accurately predict postoperative renal function and thus provide more optimal and personalized risk-based therapy options. Besides, we evaluated the association between postoperative renal function and survival.

2. Materials and Methods

2.1. Patient Selection. Following institutional review board approval and written informed consent from patients, we initially collected the clinicopathological data of 912 consecutive UTUC patients who received treatment in the Department of Urology, Peking University First Hospital, from 2000 to 2012. This was a large cohort drawing from 27 different provinces or autonomous regions of China. Patients underwent nephron-sparing surgery instead of RNU, with bilateral synchronous UTUC, and previous histories for UTUC, incomplete data on pre- or postoperative serum creatine (Scr), or no follow-up data were excluded. Six hundred and six patients were finally enrolled for evaluation.

All patients were diagnosed using computed tomography (CT) or magnetic resonance imaging (MRI), urologic ultrasound, and in some patients ureteroscopy with or without biopsy. All patients underwent surgery within two months after the occurrence of symptoms. Lower ureter and bladder cuff excision was performed through the Gibson incision in all cases. None of these patients received neoadjuvant chemotherapy (NC), while, for several patients, adjuvant chemotherapy or radiotherapy was administered when evidence of distant metastasis or retroperitoneal recurrence was documented on condition that patients had good general condition.

2.2. Patients Evaluation. The estimated glomerular filtration rate (eGFR) was calculated using the modified glomerular filtration rate estimating equation for Chinese patients: eGFR (mL/min/1.73 m²) = 175 × Scr⁻¹.234 × age⁻⁰.⁷⁷⁹ × (0.⁷⁹ if female) [16]. Comparison of eGFR before and after surgery was performed using the Scr drawn closest to 7 days after surgery (range: 3 days to 1 month after surgery). This timing was selected to best approximate the measured serum creatinine that would reflect the direct effect of RNU on renal function. And most patients could be included with available pre- and postoperative Scr data. We chose an eGFR of 60 and 45 mL/min/1.73 m² as possible cut-offs for full-dose and reduced-dose cisplatin-based AC. The eGFR cut-off of 45 mL/min/1.73 m² was defined for its compromise between lower limits for reduced-dose cisplatin in previous studies [17–19]; besides, it was cited as a more strict definition of CKD [12].

All pathological specimens were re-reviewed by a dedicated genitourinary pathologist to confirm the reproducibility of the diagnosis. Tumor stage was assessed according to the 2002 Union for International Cancer Control (UICC) TNM classification of malignant tumors. Tumor grading was assessed according to the World Health Organization (WHO) classification of 1973. Tumor architecture was defined as papillary or sessile by the examination of the final specimen. Tumor location was divided into 2 areas (renal pelvis and ureter) based on the site of the dominant lesion. Tumor multifocality was defined as the synchronous presence of two or more pathologically confirmed macroscopic tumors in any location. Ipsilateral hydronephrosis (HN) was determined by MRI or CT before operation.

2.3. Follow-Up Schedule. For patients who were followed up at our institute, the follow-up regimen of the affected patients included cystoscopy every 3 months for the first 3 years. The cystoscopy intervals were extended to 1 year thereafter. Chest X-ray, urine cytology, Scr, and abdominal ultrasound or CT/MRI were examined at the same time. The cause of death was determined by the patients' treating physicians or by death certificates. Follow-ups were censored until their last visit or death.

2.4. Statistical Analysis. Pearson's test and chi-square test were used to test the distribution of categorical variables, and the Mann-Whitney U test and paired-sample t-test were used for continuous variables. Multivariate logistic regression was used to calculate the predictive factors. Only variables that were identified as significant by the univariate analysis were considered for the multivariate analysis. Log-rank test was used in survival analysis. Multivariable logistic regression coefficients were used to generate a nomogram for impaired renal function [20]. Discrimination was measured using Harrell's Concordance index (c-index), which is similar to the area under the receiver operating characteristic curve. Calibration was measured by calibration plots, which were generated to explore the nomograms performance using 200 bootstrap resamples.

The generation of the nomogram and calibration plots was performed with the R open-source statistical software, and other statistical tests were performed with SPSS 20.0 (IBM Corp., Armonk, NY, USA). All reported P values were single-sided with statistical significance considered at P < 0.05.

3. Results and Discussion

3.1. Patients Characteristics and Changes in Renal Function. The median patient age was 69 years (range: 25–94 years). The distribution of UTUC pathological stage in this cohort...
was pTa, pT1, pT2, pT3, and pT4 in 20 (3.3%) patients, 189 (31.2%) patients, 213 (35.1%) patients, 173 (28.5%) patients, and 11 (1.8%) patients, respectively. Pathological grades 1–3 tumors were present in 18 (3.0%) individuals, 333 (55.0%) individuals, and 255 (42.1%) individuals, respectively.

Median eGFR for all patients prior to surgery was 64 (interquartile range, IQR 49–81) mL/min/1.73 m², while after RNU it was 49 (IQR 38–60) mL/min/1.73 m². Comparison of pre- and postoperative eGFR revealed a mean decrease of 15 mL/min/1.73 m² and a median percentage loss of 24% after RNU (P < 0.001).

Using 60 mL/min/1.73 m² as the eligibility cut-off for full-dose AC, 58% of the study population was eligible before surgery, whereas only 26% remained eligible following RNU. Using a cut-off of 45 mL/min/1.73 m² for reduced-dose AC, 80% was eligible preoperatively, whereas only 61.9% remained above this cut-off after surgery (Figure 1).

Only 11 patients (1.8%) in this cohort actually received AC at our institute, with mean preoperative eGFR 71.5 mL/min/1.73 m² and postoperative eGFR 54.5 mL/min/1.73 m².

3.2. Risk Factors for Impaired Renal Function. Of the 353 possible candidates for NC, 193 (54.7%) were judged ineligible to undergo AC with their postoperative eGFR below 60 mL/min/1.73 m². On univariate analysis, older age (P = 0.001), lower preoperative eGFR (P = 0.003), tumor located in renal pelvis (P = 0.007), absence of preoperative HN (P < 0.001), tumor without multifocality (P = 0.006), tumor size (P = 0.001), lower tumor stage (P = 0.001), and papillary architecture (P < 0.001) were associated with postoperative eGFR lower than 60 mL/min/1.73 m². Multivariate analysis controlling for all preoperative factors demonstrated that older age (OR = 1.007 per year), lower preoperative eGFR (OR = 0.993 per mL/min/1.73 m²), absence of preoperative HN (OR = 0.801), smaller tumor size (OR = 0.962 per centimeter), and tumor without multifocality (OR = 0.876) were independent risk factors predicting eligibility for full-dose AC (Table 1). We used logistic regression coefficients to generate a corresponding nomogram (Figure 2(a)) and calibration plot (Figure 2(b)). The accuracy of the model nomogram measured by c-index was 0.757.

Similarly, when we defined cut-off of 45 mL/min/1.73 m², preoperative eGFR (OR = 0.991 per mL/min/1.73 m²), absence of preoperative HN (OR = 0.881), tumor located in renal pelvis (OR = 1.164), and smaller tumor size (OR = 0.969) independently predicted impaired postoperative renal function in multivariate analysis (Table 2). The corresponding nomogram and calibration plot were shown in Figure 3. The accuracy of the model nomogram measured by c-index was 0.836.

3.3. Predictive Role on Survival. The median follow-up duration of this cohort of patients was 56 (IQR 24–72) months. One hundred and ninety-three patients (31.2%) died, and 166 patients (27.4%) died of urothelial cancer. The 5-year overall survival and cancer-specific survival were 69.8% and 72.6%, respectively. By log-rank test, postoperative renal function was not associated with worse OS (P = 0.077) or worse CSS (P = 0.097) (Figure 4). Besides, use of AC demonstrated no effect on survival (data not shown).

3.4. Discussion. The result of the present research confirmed that eGFR deteriorates significantly following RNU, and a substantial proportion (over 30%) of patients would miss the opportunity to undergo AC for impaired renal function, similar to previous reports [10–12]. Even when we set cut-off at 45 mL/min/1.73 m² for reduced dose of cisplatin-based chemotherapy, we could notice that although 80% of patients were qualified for NC, RNU rendered nearly 20% of patients ineligible for AC. Besides, we found no association between postoperative CKD and survival, which is in accordance with previous studies [12]. Though theoretically CKD is related to higher risk of cardiovascular events, the association of eGFR with survival in UTUC patients has not been determined and needs to be further clarified.

Due to the decline of eGFR, previous studies suggest strong consideration of neoadjuvant regimens when chemotherapy is indicated [10, 12]. But the current staging modalities hindered the extensive use of NC. As the only commonly accepted measure to get biopsy before RNU, ureteroscopy is associated with perioperative complications and higher risk of intravesical recurrence [21]. Without biopsy, we cannot firmly exclude the possibility of another pathological diagnosis instead of transitional cell carcinoma. Besides, predictive models for non-organ-confined or high-grade disease by preoperative factors in previous studies have not been testified in population-based study [22–25]. A casual NC might result in overtreatment in low-risk disease. On the other hand, AC could be carried after pathological examination of final specimen. Thus, prediction of postoperative renal function is important to detect patients not suitable for AC.

Older age and preoperative eGFR were proved to be predictive of decline of eGFR in previous reports [12, 15, 26]. There was no consensus about the predictive role of other clinical factors. Hoshino et al. [14] found the absence of higher grade HN was independent risk factor for patients ineligible for AC, while results were contrary in Rodriguez.
Table 1: Predictive factors for identifying patients ineligible to receive full dose of cisplatin-based adjuvant chemotherapy.

| Postoperative eGFR (mL/min/1.73 m²) | Univariate analysis | Multivariate analysis |
|--------------------------------------|----------------------|----------------------|
|                                      | All                  | ≥60                  | <60                  | Chi-square | P value | OR      | 95% CI    | P value |
| All, number (%)                      | 353 (100)            | 160 (45.3)          | 193 (54.7)          |            |         |         |           |         |
| Gender, number (%)                   |                      |                      |                     |            |         |         |           |         |
| Male                                 | 167 (47.3)           | 76 (47.5)           | 91 (47.2)           | 4.761      | 0.030   | 1.007   | 0.931-1.080| 0.047   |
| Female                               | 186 (52.7)           | 84 (52.5)           | 102 (52.8)          | 0.083      | 0.771   | 1.002   | 0.943-1.061| 0.149   |
| Age³, number (%)                     |                      |                      |                     |            |         |         |           |         |
| <70                                  | 200 (56.7)           | 106 (66.3)          | 94 (48.7)           | 5.567      | 0.018   | 0.971   | 0.927-1.018| 0.063   |
| ≥70                                  | 153 (43.3)           | 54 (33.8)           | 99 (51.3)           | 3.678      | 0.055   | 1.002   | 0.962-1.042| 0.874   |
| Preoperative eGFR (mL/min/1.73 m²)³, number (%) | | | | | | | | |
| <90                                  | 87 (24.6)            | 51 (31.9)           | 36 (18.7)           | 10.966     | 0.001   | 1.007   | 1.002-1.012| 0.002   |
| ≥90                                  | 266 (75.4)           | 109 (68.1)          | 157 (81.3)          | 9.235      | 0.003   | 0.993   | 0.991-0.997| <0.001  |
| Previous or concomitant BT, number (%) | 0.145                | 0.417               | 0.314               |            |         |         |           |         |
| Side, number (%)                     |                      |                      |                     |            |         |         |           |         |
| Left                                 | 173 (49.0)           | 75 (46.9)           | 98 (50.8)           | 0.533      | 0.267   | 0.533   | 0.492-0.581| 0.001   |
| Right                                | 180 (51.0)           | 85 (53.1)           | 95 (49.2)           | 0.533      | 0.267   | 0.533   | 0.492-0.581| 0.001   |
| Location, number (%)                 |                      |                      |                     |            |         |         |           |         |
| Ureter                               | 144 (40.8)           | 77 (48.1)           | 67 (34.7)           | 6.513      | 0.007   | 1.071   | 0.955-1.202| 0.240   |
| Pelvis                               | 209 (59.2)           | 83 (51.9)           | 126 (65.3)          | 6.513      | 0.007   | 1.071   | 0.955-1.202| 0.240   |
| Hydronephrosis, number (%)           | 22.657               | <0.001              | 0.801               | 0.714-0.899| <0.001  |
| DM, number (%)                       | 7.038                | 0.006               | 0.876               | 0.771-0.996| 0.044   |
| Hypertension, number (%)             |                      |                      |                     |            |         |         |           |         |
| Smoking, number (%)                  | 2.931                | 0.055               | 0.533               | 0.492-0.581| 0.001   |
| Tumor size (cm)³, number (%)         |                      |                      |                     |            |         |         |           |         |
| <3                                   | 190 (53.8)           | 71 (44.4)           | 119 (61.7)          | 10.514     | 0.001   | 0.962   | 0.942-0.983| <0.001  |
| ≥3                                   | 163 (46.2)           | 89 (55.6)           | 74 (38.3)           | 10.514     | 0.001   | 0.962   | 0.942-0.983| <0.001  |
| Architecture, number (%)             | 11.830               | <0.001              | 0.801               | 0.714-0.899| <0.001  |
| Papillary                            | 268 (75.9)           | 109 (68.1)          | 159 (82.4)          | 11.830     | <0.001  | 0.801   | 0.714-0.899| <0.001  |
| Sessile                              | 80 (22.7)            | 50 (31.3)           | 30 (15.5)           | 11.830     | <0.001  | 0.801   | 0.714-0.899| <0.001  |
| Stage, number (%)                    | 10.873               | 0.001               | 0.801               | 0.714-0.899| <0.001  |
Table 1: Continued.

|                          | Postoperative eGFR (mL/min/1.73 m²) | Univariate analysis | Multivariate analysis |
|--------------------------|-------------------------------------|---------------------|-----------------------|
|                          | All | ≥60 | <60 | Chi-square | P value | OR | 95% CI | P value |
| **Grade, number (%)**    |     |     |     |            |         |     |       |         |
| G1-2                     | 209 (59.2) | 87 (54.4) | 122 (63.2) | 2.829 | 0.058 |     |       |         |
| G3                       | 144 (40.8) | 73 (45.6) | 71 (36.8)  |     |       |     |       |         |
| **Tumor necrosis, number (%)** |     |     |     |            |         |     |       |         |
| No                       | 319 (30.4) | 140 (87.5) | 179 (92.7) | 2.766 | 0.069 |     |       |         |
| Yes                      | 34 (9.6)   | 20 (12.5)  | 14 (7.3)   |     |       |     |       |         |
| **CIS, number (%)**      |     |     |     |            |         |     |       |         |
| Absent                   | 342 (96.9) | 154 (96.3) | 188 (97.4) | 0.389 | 0.374 |     |       |         |
| Present                  | 11 (3.1)   | 6 (3.8)    | 5 (2.6)    |     |       |     |       |         |

* Statistically significant.

† Only patients with preoperative eGFR ≥ 60 mL/min/1.73 m² were included.

^ Initially calculated as binary variables in univariate analysis and used as linear variable in multivariate analysis.

OR: odds ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate; BT: bladder tumor; DM: diabetes mellitus; CIS: carcinoma in situ.

---

Figure 2: Nomogram (a) and calibration plot (b) for prediction of ineligibility to receive full-dose adjuvant chemotherapy with a c-index of 0.757.
Table 2: Predictive factors for identifying patients ineligible to receive reduced dose of cisplatin-based adjuvant chemotherapy.

| Postoperative eGFR (mL/min/1.73 m^2) | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|----------------------|
|                                      | Chi-square | P value | OR     | 95% CI | P value |
| All number (%)                       |            |         |        |        |        |
| ≥45                                  | 0.685      | 0.236   |        |        |        |
| <45                                  |            |         |        |        |        |
| Gender number (%)                    |            |         |        |        |        |
| Male                                 |            |         |        |        |        |
| Female                               |            |         |        |        |        |
| Age*, number (%)                     |            |         |        |        |        |
| <70                                  |            |         |        |        |        |
| ≥70                                  |            |         |        |        |        |
| Preoperative eGFR (mL/min/1.73 m^2)³, number (%) | 34.365 | <0.001* | 0.991  | 0.989–0.993 | <0.001* |
| <60                                  |            |         |        |        |        |
| ≥60                                  |            |         |        |        |        |
| Previous or concomitant BT, number (%) | 0.004     | 0.546   |        |        |        |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| Side number (%)                      | 0.645      | 0.244   |        |        |        |
| Left                                 |            |         |        |        |        |
| Right                                |            |         |        |        |        |
| Location number (%)                  | 9.325      | 0.002*  | 1.164  | 1.074–1.262 | <0.001* |
| Ureter                               |            |         |        |        |        |
| Pelvis                               |            |         |        |        |        |
| Hydronephrosis, number (%)           | 12.523     | <0.001* | 0.881  | 0.813–0.956 | 0.002*  |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| Multifocality, number (%)            | 0.853      | 0.215   |        |        |        |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| DM, number (%)                       | 0.091      | 0.444   |        |        |        |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| Hypertension, number (%)             | 0.877      | 0.204   |        |        |        |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| Smoking, number (%)                  | 0.276      | 0.344   |        |        |        |
| No                                   |            |         |        |        |        |
| Yes                                  |            |         |        |        |        |
| Tumor size (cm)³, number (%)         | 16.163     | <0.001* | 0.969  | 0.955–0.983 | 0.001*  |
| <3                                   |            |         |        |        |        |
| ≥3                                   |            |         |        |        |        |
| Architecture, number (%)             | 13.392     | <0.001* |        |        |        |
| Papillary                            |            |         |        |        |        |
| Sessile                              |            |         |        |        |        |
| Stage, number (%)                    | 19.838     | <0.001* |        |        |        |
| Ta/T1/T2                             |            |         |        |        |        |
| T3/T4                                |            |         |        |        |        |

* Chi-square values are significant at the 0.05 level.

² DM includes patients with diabetes mellitus.

³ Preoperative eGFR values are significantly lower than postoperative eGFR values.

⁴ Tumor size includes patients with tumors smaller than 3 cm and those with tumors larger than or equal to 3 cm.
Table 2: Continued.

|                          | Postoperative eGFR (mL/min/1.73 m²) | Univariate analysis | Multivariate analysis |
|--------------------------|-------------------------------------|---------------------|-----------------------|
|                          | All | ≥45 | <45 | Chi-square | P value | OR | 95% CI | P value |
| Grade, number (%)        |     |     |     |            |         |     |       |         |
| G1-2                     | 282 (58.1) | 204 (54.4) | 78 (70.9) | 9.525 | 0.001* |     |       |         |
| G3                       | 203 (41.9) | 171 (45.6) | 32 (29.1) |     |         |     |       |         |
| Tumor necrosis, number (%) |     |     |     |            |         |     |       |         |
| No                       | 436 (89.9) | 332 (88.5) | 104 (94.5) | 3.385 | 0.043* |     |       |         |
| Yes                      | 49 (10.1) | 43 (11.5) | 6 (5.5) |     |         |     |       |         |
| CIS, number (%)          |     |     |     |            |         |     |       |         |
| Absent                   | 471 (97.1) | 363 (96.8) | 108 (98.2) | 0.579 | 0.350 |     |       |         |
| Present                  | 14 (2.9) | 12 (3.2) | 2 (1.8) |     |         |     |       |         |

*Statistically significant.

Only patients with preoperative eGFR ≥ 45 mL/min/1.73 m² were included.

Initially calculated as binary variables in univariate analysis and used as linear variable in multivariate analysis.

OR: odds ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate; BT: bladder tumor; DM: diabetes mellitus; CIS: carcinoma in situ.

Figure 3: Nomogram (a) and calibration plot (b) for prediction of ineligibility to receive reduced-dose adjuvant chemotherapy with a c-index of 0.836.
Figures 4: Estimated Kaplan-Meier overall survival curves (a) \( (P = 0.077) \) and cancer-specific survival curves (b) \( (P = 0.097) \) stratified by postoperative renal function.

Faba’s research [15]. No explanation for these results was provided in these studies. A probable hypothesis for our results is that the presence of HN was always accompanied by thinner renal cortex and reduced eGFR. Total renal function would be compensated by the contralateral kidney. Thus, the resection of the impaired kidney would not result in significant decline of total eGFR as it only takes a small proportion. For patients with same preoperative eGFR, those with ipsilateral HN would probably have a better contralateral kidney and, as a result, a probable higher postoperative eGFR. Similarly, although not evidenced in previous clinical trials, it is easy to deduce that large tumor size, multifocality, and ureteral location would be associated with impaired function of the kidney with tumor (the kidney that would be removed); thus, they were demonstrated to be “protective” factor for postoperative eGFR after adjusting for preoperative renal function.

It is a pity that in most patients split renal function studies by nuclear renal scans were not routinely obtained before surgery. Evidence is scarce but, considering its function in evaluating the preoperative eGFR of the contralateral kidney directly, it might play an important role in predictive postoperative renal function after RNU.

Our model could help clinicians in optimizing timing of chemotherapy regimens and providing personalized therapy options based on preoperative factors. For patients evaluated as high risk for postoperative renal insufficiency, if systematic chemotherapy is considered, NC is recommended before their renal function is impaired, while, for patients less likely to suffer from decreased eGFR lower than 60 mL/min/1.73 m², clinicians could carefully evaluate the necessity of NC. Unless strongly indicated (e.g., high grade in biopsy, suspicious of lymph node metastasis, and/or adjacent organs invaded), clinicians could perform RNU without delay and carry AC if required based on final pathology.

NC has been demonstrated to decrease tumor burden and improve patients’ survival [8, 27], while the effect of AC on prognosis was unsatisfied [5–7, 28, 29]. However, many of these trials were retrospective, single-center study with small sample size, and the regimen as well as doses was limited by poor postoperative renal function and was not standardized. Although the previous results of NC are promising, we should not neglect the possible benefits of AC which clearly needs more research.

There are some limitations in our study, especially the limitation of retrospective itself, and our study cohort might have been subject to selection and recall bias. Additionally, since we focused on early time-points in postoperative Scr, we could not exclude the possibility of spuriously low Scr measurements due to perioperative intravenous hydration or spuriously high Scr measurements as it is too early for the contralateral kidney to fully compensate. But our result could be interpreted as evaluation of acute renal disease short-term after RNU, and Kaag et al. [13] demonstrated that the decline of renal function after RNU showed no evidence of recovery over time. Another limitation is that, due to various reasons, there were extremely few patients that actually received AC.

Despite these limitations, to our knowledge, it is the first research that provides an applicable tool to predict postoperative renal insufficiency that could help risk stratification and
treatment strategies selection. Future studies on long-term monitoring of renal function and prospective clinical trials on AC would be required.

4. Conclusions

In the Chinese patients with UTUC, older age, lower preoperative eGFR, smaller tumor size, tumor located in renal pelvis, and absence of HN or tumor multifocality were demonstrated to be significant predictors of impaired renal function following RNU. The nomogram accurately predicts ineligibility for AC. Postoperative renal function did not correlate with patients’ survival. The clinical significance of those results needs to be further assessed in external multi-institutional validation cohorts.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Dong Fang and Qifu Zhang contributed equally to this paper.

Acknowledgments

This work was supported by Grants from the Collaborative Research Foundation of Peking University Health Science Center and National Taiwan University, College of Medicine (BMU20120318), Natural Science Foundation of Beijing (7122183), Natural Science Foundation of Peking University Health Science Center and National Taiwan University, College of Medicine. The authors thank the entire staff of the Department of Urology, Peking University First Hospital.

References

[1] K. B. Cummings, “Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract,” Urologic Clinics of North America, vol. 7, no. 3, pp. 569–578, 1980.
[2] M. Craig Hall, S. Womack, A. I. Sagalowsky, T. Carmody, M. D. Erickstad, and C. G. Roehrborn, “Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients,” Urology, vol. 52, no. 4, pp. 594–601, 1998.
[3] A. Berger, G. Haber, K. Kamoi et al., “Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: oncological outcomes at 7 years,” Journal of Urology, vol. 180, no. 3, pp. 849–854, 2008.
[4] V. Margulis, S. F. Shariat, S. E. Matin et al., “Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration,” Cancer, vol. 115, no. 6, pp. 1224–1233, 2009.
[5] C. Kwak, S. E. Lee, I. G. Jeong, and J. H. Ku, “Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract,” Urology, vol. 68, no. 1, pp. 53–57, 2006.
[6] N. J. Hellenthal, S. F. Shariat, V. Margulis et al., “Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration,” Journal of Urology, vol. 182, no. 3, pp. 900–906, 2009.
[7] M. Vassilakopoulou, T. de La Motte Rouge, P. Colin et al., “Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UTUC): Results from a large multicenter collaborative study,” Cancer, vol. 117, no. 24, pp. 5500–5508, 2011.
[8] S. F. Matin, V. Margulis, A. Kamat et al., “Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma,” Cancer, vol. 116, no. 13, pp. 3127–3134, 2010.
[9] A. Dahal, B. K. Bellows, G. Sonpavde et al., “Incidence of severe nephrotoxicity with cisplatin based on renal function eligibility criteria: indirect comparison meta-analysis,” American Journal of Clinical Oncology, 2014.
[10] M. G. Kaag, R. L. O’Malley, P. O’Malley et al., “Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy,” European Urology, vol. 58, no. 4, pp. 581–587, 2010.
[11] B. R. Lane, A. K. Smith, B. T. Larson et al., “Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy,” Cancer, vol. 116, no. 12, pp. 2967–2973, 2010.
[12] E. Xylinas, M. Rink, V. Margulis et al., “Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy,” BJU International, vol. 112, no. 4, pp. 453–461, 2013.
[13] M. Kaag, L. Trost, R. H. Thompson et al., “Pre-operative predictors of renal function decline following radical nephroureterectomy for upper tract urothelial carcinoma,” BJU International, 2013.
[14] K. Hoshino, E. Kikuchi, N. Tanaka et al., “Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy,” Japanese Journal of Clinical Oncology, vol. 42, no. 3, Article ID hyr199, pp. 202–207, 2012.
[15] O. Rodriguez Faba, J. Palou, A. Breda et al., “Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma,” Urology International, vol. 92, no. 2, pp. 169–173, 2014.
[16] Y. Ma, L. Zuo, J. Chen et al., “Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease,” Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 2937–2944, 2006.
[17] S. A. Hussain, D. D. Stocken, P. Riley et al., “A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer,” British Journal of Cancer, vol. 91, no. 5, pp. 844–849, 2004.
[18] A. Bamias, C. Deliveliotis, G. Fountzilas et al., “Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2150–2154, 2004.
[19] R. De Wit, “Overview of bladder cancer trials in the European Organization for Research and Treatment,” Cancer, vol. 97, no. 8, pp. 2120–2126, 2003.
[20] F. E. Harrell, “Binary logistic regression,” in Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, pp. 215–268, Springer, New York, NY, USA, 2001.
[21] H. L. Luo, C. H. Kang, Y. T. Chen et al., “Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma,” *Annals of Surgical Oncology*, vol. 20, no. 9, pp. 3121–3126, 2013.

[22] R. L. Favaretto, S. F. Shariat, C. Savage et al., “Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma,” *BJU International*, vol. 109, no. 1, pp. 77–82, 2012.

[23] J. C. Brien, S. F. Shariat, M. P. Herman et al., “Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma,” *Journal of Urology*, vol. 184, no. 1, pp. 69–73, 2010.

[24] V. Margulis, R. F. Youssef, P. I. Karakiewicz et al., “Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract,” *Journal of Urology*, vol. 184, no. 2, pp. 453–458, 2010.

[25] X. Chen, G. Xiong, X. Li et al., “Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China,” *BJU International*, vol. 112, no. 7, pp. 917–924, 2013.

[26] J. Meyer, G. H. Delves, M. E. Sullivan, and S. R. Keoghane, “The effect of nephroureterectomy on glomerular filtration rate,” *BJU International*, vol. 98, no. 4, pp. 845–848, 2006.

[27] I. Igawa, S. Urakami, H. Shiina et al., “Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract,” *Urologia Internationalis*, vol. 55, no. 2, pp. 74–77, 1995.

[28] N. Soga, K. Arima, and Y. Sugimura, “Adjuvant methotrexate, vinblastine, Adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma,” *International Journal of Urology*, vol. 15, no. 9, pp. 800–803, 2008.

[29] F. A. Yafi, S. Tanguay, R. Rendon et al., “Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome,” *Urologic Oncology: Seminars and Original Investigations*, vol. 32, no. 1, pp. e17–e24, 2013.